Korean Journal of Nephrology 2007;26(4):435-439.
The Clinical Study on Aluminum Levels in Patients Undergoing Hemodialysis
Yun Seok Seo, M.D., Hyo Wook Gil, M.D., Jong Oh Yang, M.D., Eun Young Lee, M.D. and Sae-Yong Hong, M.D.
Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea
혈액 투석환자에서 혈중 알루미늄 농도에 관한 임상적 고찰
순천향대학교 천안병원 신장내과
: This study was performed to evaluate the aluminum level in hemodialysis patients and to find a correlation between aluminum level and bone specific alkaline phosphatase level.
: Eighty five randomly selected patients with end-stage renal disease, undergoing maintenance hemodialysis treatment over 1 year were studied. Serum aluminum and bone specific alkaline phosphatase concentration were measured. Low dose desferrioxamine test (5 mg/kg) was done.
: The serum aluminum concentration before and after low dose desferrioxamine test were 4.21±2.13 μg/L and 8.89±4.48 μg/L (p<0.01) respectively. Bone-specific alkaline phosphates and parathyroid hormone concentration were 39.08±39.90 mg/dL and 98.27±112.92 pg/mL. The aluminum level after desferrioxamine test was correlated with duration of hemodialysis (r=0.238, p=0.03). Aluminum level was not correlated with bone specific alkaline phosphatase level.
: Aluminum level was lower than that of previous studies. Aluminum level was not increased in patients with low bone specific alkaline phosphatase. Thus, it seems that serum aluminum level is not a major problem in hemodialysis patients with lower turnover bone disease. However, confirm diagnosis of aluminum related bone disease in hemodialysis patients needs combined study of bone histology with a large number of cases.
Key Words: Aluminum, Hemodialysis, Renal osteodystrophy

Editorial Office
#301, (Miseung Bldg.) 23, Apgujenog-ro 30-gil, Gangnam-gu, Seoul 06022, Korea
Tel: +82-2-3486-8736    Fax: +82-2-3486-8737    E-mail: registry@ksn.or.kr                

Copyright © 2023 by The Korean Society of Nephrology.

Developed in M2PI

Close layer